Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Change in Accured Expenses (2016 - 2020)

Historic Change in Accured Expenses for Larimar Therapeutics (LRMR) over the last 8 years, with Q4 2020 value amounting to $2.5 million.

  • Larimar Therapeutics' Change in Accured Expenses rose 47597.01% to $2.5 million in Q4 2020 from the same period last year, while for Dec 2020 it was $3.2 million, marking a year-over-year increase of 24201.06%. This contributed to the annual value of $13.4 million for FY2024, which is 141467.71% up from last year.
  • Per Larimar Therapeutics' latest filing, its Change in Accured Expenses stood at $2.5 million for Q4 2020, which was up 47597.01% from -$354000.0 recorded in Q3 2020.
  • Larimar Therapeutics' Change in Accured Expenses' 5-year high stood at $2.5 million during Q4 2020, with a 5-year trough of -$1.7 million in Q2 2016.
  • Its 5-year average for Change in Accured Expenses is $156300.0, with a median of $181000.0 in 2017.
  • In the last 5 years, Larimar Therapeutics' Change in Accured Expenses plummeted by 49924.24% in 2018 and then soared by 47597.01% in 2020.
  • Quarter analysis of 5 years shows Larimar Therapeutics' Change in Accured Expenses stood at -$843000.0 in 2016, then surged by 240.57% to $1.2 million in 2017, then crashed by 140.51% to -$480000.0 in 2018, then tumbled by 39.58% to -$670000.0 in 2019, then surged by 475.97% to $2.5 million in 2020.
  • Its Change in Accured Expenses stands at $2.5 million for Q4 2020, versus -$354000.0 for Q3 2020 and $837000.0 for Q2 2020.